Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective decreases in regulatory B cell (Breg) subsets in active uveitis: IL-10+CD19+CD24hiCD38hiBreg in patients and B10 Breg in mice.

International immunology·2026
Same author

Adalimumab biosimilars have similar efficacy to originator adalimumab when treating non-infectious uveitis.

The British journal of ophthalmology·2025
Same author

Impact of microorganism virulence on endophthalmitis outcomes.

The British journal of ophthalmology·2024
Same author

Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy.

Progress in retinal and eye research·2024
Same author

Can Simvastatin Reduce the Need for Immunomodulatory Drugs to Treat Uveitis?: A Prospective, Randomized, Placebo-Controlled Trial.

Ophthalmology science·2023
Same author

Comparison of anatomical and functional outcomes of treating myopic choroidal neovascularization with bevacizumab or ranibizumab.

International ophthalmology·2023
Same journal

The risk of retinal vascular events in patients using semaglutide: a scoping review.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

Interpreting relative afferent pupillary defect in Leber hereditary optic neuropathy using interocular visual acuity difference.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

1 MONTH VS. 3 MONTHS HEAVY SILICONE OIL TAMPONADE IN COMPLEX RHEGMATOGENOUS RETINAL REDETACHMENT.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

Visual loss after silicone oil removal - Analysis of a German cohort.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

Weekend effect on vitrectomy: Insights from a Nationwide Population-Based Study in Korea.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

The Royal College of Ophthalmologists National Ophthalmology Database Age-related Macular Degeneration (AMD) Audit, Report 2: Baseline characteristics, the care pathway and 12-month visual acuity and safety outcomes for 54,882 eyes starting treatment for neovascular AMD.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

New developments in corticosteroid therapy for uveitis.

Simon R J Taylor1, Hazlita Isa, Lavnish Joshi

  • 1UCL Institute of Ophthalmology, London, UK.

Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde
|August 18, 2010
PubMed
Summary
This summary is machine-generated.

Corticosteroids are key for uveitis management. New sustained-release intraocular implants offer effective, long-term treatment with improved safety profiles compared to repeated injections.

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Related Experiment Videos

Last Updated: Jun 10, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Corticosteroids are the primary treatment for uveitis.
  • Topical corticosteroids manage anterior uveitis; systemic corticosteroids treat posterior segment inflammation.
  • Local corticosteroid therapy, including periocular injections and intraocular injections, offers advantages for unilateral or localized ocular inflammation.

Purpose of the Study:

  • To review the evolving role of corticosteroids in uveitis management.
  • To evaluate the efficacy and safety of novel intraocular corticosteroid delivery systems.

Main Methods:

  • Review of current literature on corticosteroid use in uveitis.
  • Discussion of topical, systemic, periocular, and intraocular corticosteroid administration.
  • Analysis of new sustained-release intraocular corticosteroid implants (Retisert, Ozurdex).

Main Results:

  • Intraocular corticosteroids like triamcinolone can reduce macular edema and improve vision in refractory uveitis.
  • Newer implants like Retisert (fluocinolone) and Ozurdex (dexamethasone) provide sustained drug delivery.
  • Ozurdex demonstrates comparable efficacy to other methods with a potentially better side effect profile and longer duration of action than repeated injections.

Conclusions:

  • Sustained-release intraocular corticosteroid implants represent a significant advancement in uveitis treatment.
  • These devices may reduce the need for systemic immunosuppression and offer improved safety and convenience.
  • Further research into long-term outcomes and comparative effectiveness of these implants is warranted.